COVID-19 vaccinations in patients with inflammatory bowel disease

Affiliations

¹ Royal Wolverhampton Trust, New Cross Hospital, Wolverhampton WV10 0QP, UK; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK. Electronic address: aditikumar@nhs.net.
² University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK; Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³ Department of Gastroenterology and Hepatology, St Mary's Hospital London, London, UK.
⁴ Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK.
⁵ Royal Wolverhampton Trust, New Cross Hospital, Wolverhampton WV10 0QP, UK; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK.

Comment

Aditi Kumar et al. Lancet Gastroenterol Hepatol. 2020 Nov.

. 2020 Nov;5(11):965-966.

doi: 10.1016/S2468-1253(20)30295-8. Epub 2020 Sep 21.

¹ Royal Wolverhampton Trust, New Cross Hospital, Wolverhampton WV10 0QP, UK; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK. Electronic address: aditikumar@nhs.net.
² University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK; Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
³ Department of Gastroenterology and Hepatology, St Mary's Hospital London, London, UK.
⁴ Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK.
⁵ Royal Wolverhampton Trust, New Cross Hospital, Wolverhampton WV10 0QP, UK; Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK.

No abstract available

Comment on

Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.
Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Melmed GY, et al. Am J Gastroenterol. 2006 Aug;101(8):1834-40. doi: 10.1111/j.1572-0241.2006.00646.x. Epub 2006 Jun 30. Am J Gastroenterol. 2006. PMID: 16817843

1. Fiorino G, Peyrin-Biroulet L, Naccarato P. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042–1047. - PubMed
1. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Coronavirus and IBD reporting database: current data. https://covidibd.org/current-data/
1. Pan D, Sze S, Minhas JS. The impact of ethnicity on clinical outcomes in COVID-19: a systematic review. EClinicalMedicine. 2020;23 - PMC - PubMed
1. Folegatti PM, Ewer KJ, Aley PK. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. - PMC - PubMed
1. Melmed GY, Ippoliti AF, Papadakis KA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–1840. - PubMed